Welcome to our dedicated page for Genvor news (Ticker: GNVR), a resource for investors and traders seeking the latest updates and insights on Genvor stock.
Genvor Inc. develops AI-assisted peptide discovery technology for agriculture, health and wellness applications. Company news centers on its BioCypher platform, peptide research, sustainable crop-protection technology, human wellness expansion, commercialization partnerships and executive business-development appointments.
Recurring updates include peer-reviewed validation of AGM182 antifungal peptide technology, research collaborations, conference presentations and strategic commercialization frameworks. News also covers Genvor's movement from agriculture-focused peptide programs into broader health, recovery, performance and wellness categories.
Genvor (OTCQB: GNVR) appointed Donald Kalkofen as Chief Financial Officer, effective May 21, 2026. He will lead financial strategy as Genvor advances commercialization across agriculture and human health.
Kalkofen brings 20+ years of CFO experience, including IPOs, NASDAQ listings, SOX 404(b) implementation, and senior roles at biotech, technology, and banking companies.
Genvor (OTCQB: GNVR) executed a non-binding Memorandum of Understanding with Canlab International on April 14, 2026 to develop, manufacture and commercialize a multi-product peptide pipeline across weight management, anti-aging, tissue repair, hair restoration and hormonal optimization.
Planned near-term steps include initiating development of ~5 peptide candidates in 2026 with a roadmap to expand to 20+ candidates, leveraging Canlab’s network of >5,000 physicians and 500 medical spa operators and contemplated economic structures including ~11% royalties or ~$1M target annual payments per target, subject to definitive agreements and validation.
Genvor (OTCQB: GNVR) will present at the Centri Capital Conference on April 14, 2026 at Nasdaq in New York City. CEO Chad Pawlak will discuss recent performance and growth plans during investor presentations, 1:1 meetings, and panel sessions attended by capital markets participants.
The event includes sponsor support from major capital-markets firms and aims to connect companies with investment bankers, private equity, family offices, and HNW investors.
Genvor (OTCQB:GNVR) announced that CEO Chad Pawlak will present a corporate update at the National Investment Banking Association's 152nd Investment Conference in Fort Lauderdale on March 12, 2026.
The presentation will cover the company's AI-accelerated peptide platform, recent milestones, technology advancements and upcoming growth initiatives; management will be available for one-on-one investor meetings.
Genvor (OTCQB: GNVR) announced a strategic expansion into the human health and wellness market on March 4, 2026, leveraging its proprietary BioCypher AI-driven peptide platform.
The company said its library contains millions of designed peptides, with dozens of agricultural lead candidates across more than a dozen pathogens, and will now advance consumer-focused recovery, performance, anti-aging, and daily wellness peptide products via a dual commercialization model.
Genvor also realigned senior leadership, assigning George Stavrides expanded oversight of agricultural commercialization while CEO Chad Pawlak focuses on capital markets and consumer partnership development.
Genvor (OTCQB: GNVR) announced peer-reviewed validation of its AI-designed antifungal peptide AGM182 in PhytoFrontiers, reporting greenhouse results showing 76–98% reduction in total aflatoxin contamination in transgenic corn expressing AGM182.
The publication, co-authored with USDA-ARS, cites no adverse plant growth effects, a proven mammalian safety profile, activity versus Aspergillus flavus and Fusarium species, and follows U.S. Patent No. 12,458,684 co-assigned with USDA-ARS.
Genvor (OTCQB: GNVR) appointed Dr. George Stavrides as Executive Vice President, Business Development & Commercialization, effective February 2, 2026. Dr. Stavrides brings 15+ years in agrochemical and biological product management, including roles at Syngenta where he oversaw >50 global product launches and helped quadruple revenues over seven years.
He will lead commercial strategy, partnerships, licensing and collaboration efforts to advance Genvor’s AI-accelerated peptide platform and expand market access to growers worldwide.
Genvor (OTC: GNVR) will present at the 3rd Annual DealFlow Discovery Conference on January 28-29, 2026, at The Borgata Hotel, Casino & Spa in Atlantic City, New Jersey.
Co-Founder Clayton Yates, MS, Ph.D. will deliver a company presentation on January 28 at 11:00 AM EST and will be available for one-on-one investor meetings during the event. The presentation will describe how Genvor’s AI-accelerated peptide platform targets plant pathogens linked to an estimated $220 billion in annual crop losses.
Genvor (OTC: GNVR) entered a formal teaming agreement with Tuskegee University on December 2, 2025 to accelerate peptide-based technologies for sustainable crop protection.
The collaboration establishes joint research, testing, and grant-supported development, giving Genvor access to Tuskegee research laboratories, instrumentation, and student talent to expand scientific validation and field application of Genvor’s proprietary peptide active ingredients.
Genvor (OTCQB: GNVR) announced the USPTO issued U.S. Patent No. 12,458,684 on Nov 12, 2025 for “Transgenic Corn with Antifungal Peptide AGM182,” co‑assigned to Genvor and the USDA. The patent covers transgenic corn expressing AGM182 designed to reduce fungal infections and mycotoxin accumulation, including activity shown against Aspergillus flavus and Fusarium species.
Published results cited in Plant Science and Plant Disease report 76–98% reduction in total aflatoxin contamination, no adverse plant growth or yield effects, and no observed mammalian toxicity. The company highlights potential foliar spray and transgenic seed applications to address multi‑billion dollar U.S. corn losses from fungal diseases.